From the Journals

Sickle cell patients with vitamin D deficiency prone to more ED visits, longer stays


 

FROM BLOOD CELLS, MOLECULES, AND DISEASES

Patients with sickle cell disease (SCD) plus vitamin D deficiency were found to have more hospitalization outcomes, including number of emergency department (ED) visits, the number of hospital admissions for pain crisis, and the length of hospital admission, according to a study published online by researchers from New York-Presbyterian Brooklyn Methodist Hospital.

A cluster of sickle cell anemia blood cells. Dr_Microbe/Thinkstock

The researchers performed a retrospective chart review of all 134 pediatric patients with SCD (aged 1-21 years) from January 2015 to January 2016 in an urban-based hospital setting. Ninety patients with at least one reported vitamin D level who maintained follow-up during the time studied were enrolled. Hospitalization rates were compared between vitamin D deficiency (< 20 ng/mL) and sufficiency (> 20 ng/mL) patients.

When compared to patients with SCD and sufficient vitamin D levels, patients with both SCD and vitamin D deficiency were more likely to have at least one ED visit (P < .01), at least one admission for pain crisis (P < .01), and a longer length of admission (P < .0001), the researchers found.

“Screening and treatment for vitamin D deficiency is generally cost effective and readily available, potentially having a significant impact on the quality of life for those living with sickle cell disease,” the researchers concluded.

The authors reported that there was no study funding and that they had no conflicts of interest.

SOURCE: Brown B et al. Blood Cells Mol Dis. 2020. doi: 10.1016/j.bcmd.2020.102415.

Recommended Reading

Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
MDedge Hematology and Oncology
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
MDedge Hematology and Oncology
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
MDedge Hematology and Oncology
BCL11A-directed gene therapy advances in sickle cell disease
MDedge Hematology and Oncology
The evolving landscape of complement inhibition therapy
MDedge Hematology and Oncology
Sevuparin failed for acute VOC in sickle cell, but may have preventive potential
MDedge Hematology and Oncology
Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias
MDedge Hematology and Oncology
Flow-mediated dilation of brachial artery predicts renal dysfunction in sickle cell disease
MDedge Hematology and Oncology
Genetic testing helps avoid false hemoglobinopathy diagnoses in newborns
MDedge Hematology and Oncology
Chimerism and the use of fludarabine associated with secondary graft failure in aplastic anemia
MDedge Hematology and Oncology